Elevated NKT cell levels in adults with severe chronic immune thrombocytopenia

  • Authors:
    • Ruilong Xu
    • Zhaojing Zheng
    • Yongjun Ma
    • Yingping Hu
    • Shunhong Zhuang
    • Bin Wei
    • Jianxing Lu
  • View Affiliations

  • Published online on: November 6, 2013     https://doi.org/10.3892/etm.2013.1386
  • Pages: 149-154
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The aim of this study was to investigate the frequency of circulating natural killer T (NKT) cells and regulatory T cells (Tregs), as well as serum cytokine profiles, in adult chronic primary immune thrombocytopenia (ITP). The frequency of circulating T cell receptor (TCR) Vα24+Vβ11+CD3+ NKT cells and CD4+CD25+CD127‑/low Tregs was measured using multi‑color flow cytometry. The serum concentrations of 11 cytokines were determined with a cytometric bead assay. The frequency of circulating NKT cells in patients with ITP was 0.13±0.03%, whereas the frequency in healthy controls was 0.07±0.01% of CD3+ (P>0.05). However, the frequency of NKT cells in patients with ITP with platelet counts ≤20x109/l (0.22±0.05%) was significantly higher than that in patients with platelet counts >20x109/l (0.05±0.01%; P<0.05) and that in healthy controls (0.07±0.01%; P<0.05). The frequency of peripheral Tregs was comparable between patients with ITP (3.97±0.44% of CD4+) and healthy controls (3.69±0.31%; P>0.05). No significant differences were observed in the serum concentrations of 11 cytokines between patients with ITP and healthy controls, despite the fact that the serum levels of interleukin (IL)‑12p70, IL‑8, IL‑4, interferon (IFN)‑γ and tumor necrosis factor (TNF)‑α in patients with ITP were higher than those in the healthy controls. The platelet count was negatively correlated with the frequency of circulating NKT cells in chronic ITP. These results indicate that NKT cells may be involved in ITP with severe thrombocytopenia, and NKT and Tregs may be important in cytokine deregulation in chronic ITP.

Introduction

Primary immune thrombocytopenia (ITP) is an acquired immune-mediated disorder characterized by isolated thrombocytopenia, which is defined as a peripheral blood platelet count of <100×109/l and the absence of any clear initiating and/or underlying cause (1). Antibodies that are autoreactive to platelet antigens, mainly the platelet glycoprotein IIb/IIIa complex, are considered responsible for the reduced platelet production and accelerated destruction of platelets by the reticuloendothelial system (2,3). Platelet antigen-specific T cells are activated upon the recognition of platelet auto-antigens and induce the production of auto-antibodies by B cells in patients with ITP (4,5). ITP has been further suggested to be a T helper (Th)-1-polarized autoimmune disease (68). These data are consistent with a loss of peripheral tolerance and an inflammatory phenotype in patients with chronic ITP.

CD4+CD25+ regulatory T cells (Tregs) are critical in the maintenance of peripheral tolerance and directly and indirectly suppress the activation and proliferation of numerous cell types, including T, B, dendritic, natural killer and natural killer T (NKT) cells in vivo and/or in vitro(9). A number of studies have been conducted to investigate the roles of Tregs in ITP, particularly in chronic ITP; however, the results have not always been consistent (1012). Liu et al(10) and Sakakura et al(11) observed that the level of Tregs was significantly decreased in the circulation in ITP. By contrast, Yu et al(12) demonstrated that the level of circulating Tregs was comparable between patients with ITP and the controls; however, the inhibitory activity of the Tregs isolated from the patients with ITP was two-fold lower than that of the Tregs from the controls.

NKT cells are another T lymphocyte subset with regulatory functions involved in peripheral tolerance in humans, and are characterized by invariant expression of the T cell receptor (TCR) Vα24 and Vβ11 chains (13). The levels and functional status of NKT cells are associated with multiple human autoimmune diseases; however, the mechanisms have yet to be elucidated (14). Johansson et al(15) demonstrated that the levels of circulating NKT cells decreased in patients with ITP, which suggested the involvement of NKT cells in ITP pathogenesis.

NKT cells and Tregs interact with each other and contribute functionally to a sophisticated network of immune regulation in humans (16). However, few studies have described the changes in levels of circulating Tregs and NKT cells in ITP. In this study, the frequency of peripheral Tregs and NKT cells and the Th1/Th2 cytokine profile were analyzed, and a correlation analysis was performed between the immune response and the disease phenotypes in adult chronic ITP.

Materials and methods

Subjects

Sixty-eight patients with chronic ITP, who were hospitalized in the Department of Hematology, Jinhua Hospital of Zhejiang University (Jinhua, China) from January 2008 to March 2010, were included in this study. An additional 38 healthy age- and gender-matched volunteers were used as controls. Gender, mean age and platelet count from the ITP and control groups are summarized in Table I. The diagnosis of chronic ITP was in agreement with the standards proposed by Zhang et al(17), i.e., a platelet count of <50×109/l for more than six months, normal or increased bone marrow, megakaryocytes without any features of dysplasia and a lack of other known causes, such as systemic lupus erythematosus. In the two weeks prior to sampling, none of the patients or healthy volunteers took corticosteroids or other medications that may have affected platelet metabolism. All patients were in the active phase and were divided into two groups according to platelet count: <20×109/l (n=30) and >20×109/l (n=38). This study was conducted in accordance with the Declaration of Helsinki and with approval from the ethics committees of Jinhua Hospital of Zhejiang University and Wenzhou Medical University (Wenzhou, China). Written informed consent was obtained from all participants.

Table I

Summary of the clinical and laboratory parameters of the study subjects.

Table I

Summary of the clinical and laboratory parameters of the study subjects.

GroupMale/female (n/n)Age (years)PLT (x109/l)
ITP40/2843.82±2.4626.69±3.90
Control24/1438.53±1.97230.84±11.29

[i] Results are presented as the mean ± standard deviation. ITP, immune thrombocytopenia; PLT, platelet count.

Preparation of peripheral blood mononuclear cells (PBMCs)

EDTA-K2 anti-coagulated venous blood, collected from patients and healthy volunteers, was diluted with an equivalent volume of saline. According to standard procedures, PBMCs were separated over Lymphoprep™ 1.077 medium (Axis-Shield PoC, Oslo, Norway), washed three times and suspended in pH 7.4 phosphate-buffered saline (PBS) with an adjusted cell density of 5×106/ml.

Measurement of CD4+CD25+CD127−/low cells

PBMCs were stained with a cocktail of fluorescein isothiocyanate (FITC) anti-human CD4, phycoerythrin (PE) anti-human CD25, CD127-PE-Cy5 and immunoglobulin (Ig) G1-PE-Cy5 (all from eBioscience, Inc., San Diego, CA, USA) for 15 min at room temperature in the dark, washed three times with pH 7.4 PBS and resuspended in PBS. The frequency of CD4+CD25+CD127−/low cells was determined by three-color flow cytometry on a Beckman-Coulter Epics XL flow cytometer (Beckman-Coulter, Inc., Brea, CA, USA). Flow-Check™ fluorospheres (Beckman-Coulter, Inc.) were used in the daily alignment and verification of the flow cytometer optics and fluidics. Data acquisition and analysis were performed using the Expo32 ADC software package (Applied Cytometry, Dinnington, UK). Tregs were identified as CD4+CD25+CD127−/low and the frequency of Tregs was expressed as the percentage of CD4+ cells. A total of ≥70,000 CD4+ events were analyzed in each experiment.

Measurement of TCRVα24+Vβ11+ T cells

PBMCs were stained with CD3-PE-Cy5, Vα24-FITC and Vβ11-PE (all from Beckman-Coulter, Inc.) for 15 min at room temperature in the dark, washed three times with pH 7.4 PBS and resuspended in PBS. Simultaneously, isotype controls were set with IgG1-FITC and IgG2a-PE (Beckman-Coulter, Inc.). NKT cells were identified as CD3+Vα24+Vβ11+ and the frequency of NKT cells was expressed as the percentage of CD3+ cells. A total of ≥100,000 CD3+ events were analyzed in each experiment.

Th1/Th2 cytokine profiling

Serum was collected from each patient and healthy volunteer and stored in a −76°C ultra-low temperature freezer (Thermo Fisher Scientific, Inc., Middletown, VA, USA) until analysis. Serum Th1/Th2 cytokine profiles were determined using a cytometric bead array (CBA) Human Th1/Th2 Cytokine 11-plex kit (eBioscience, Campus Vienna-Biocenter 2, Vienna, Austria) and 11 cytokines, interleukin (IL)-12p70, IL-10, IL-2, IL-8, IL-6, IL-5, IL-4, IL-1β, interferon (IFN)-γ, tumor necrosis factor (TNF)-α and TNF-β, were analyzed. The experimental procedures were in strict accordance with the manufacturer’s instructions. Data were acquired through the Expo32 ADC software package (Applied Cytometry) on a Beckman-Coulter Epics XL flow cytometer (Beckman-Coulter, Inc.). Data analysis was performed using FlowCytomix™ Pro 2.3 (eBioscience, Campus Vienna-Biocenter 2). The concentration of serum cytokines was expressed in pg/ml.

Statistical analysis

Data were processed statistically using SPSS 16.0 (SPSS, Inc., Chicago, IL, USA) and GraphPad Prism 4.0 (GraphPad Software, Inc., La Jolla, CA, USA) software. A Student’s t-test was used to compare two independent samples, while one-way analysis of variance (ANOVA) was used for multiple comparisons. A least significant difference (LSD) test was performed for comparisons in which equal variances were assumed and Dunnett’s T3 test was used for comparisons in which equal variances were not assumed. Non-parametric comparisons were conducted using Pearson’s χ2 test and a linear regression model was used for correlation analysis. P<0.05 was considered to indicate a statistically significant difference.

Results

Measurement of NKT cells

The level of NKT cells (Fig. 1) in patients with chronic ITP was higher than that in the controls (0.13±0.03 versus 0.07±0.01% of CD3+); however, the difference was not statistically significant (P>0.05). The results showed that the frequency of NKT cells was significantly elevated in patients with platelet counts ≤20×109/l (0.22±0.05%) compared with the frequency of NKT cells in patients with platelet counts >20×109/l (0.05±0.01%; P<0.05) and in controls (0.07±0.01%; P<0.05); however, no significant difference was observed between the latter two groups.

Frequency of Tregs

The frequency of circulating Tregs (Fig. 2) in patients with chronic ITP was 3.97±0.44% of CD4+, which was comparable to 3.69±0.31% in the control group (P>0.05). Compared with Treg level in the patients with platelet counts >20×109/l (3.78±0.59%), the level of Tregs was elevated in patients with chronic ITP with platelet counts ≤20×109/l (4.21±0.67%); however, the difference was not statistically significant (P>0.05).

Th1/Th2 cytokine ratio

No significant differences were observed in the serum levels of IL-12p70, IL-10, IL-2, IL-8, IL-6, IL-5, IL-4, IL-1β, IFN-γ, TNF-α or TNF-β between the patients with ITP and the controls (Table II). The Th1 cytokine (IFN-γ, IL-2)/Th2 cytokine (IL-4, IL-5) ratio was calculated, which was used to predict the disease-specific Th cell polarization. The type 1 cytokine (IFN-γ, IL-2, IL-12p70 and TNF-β)/type 2 cytokine (IL-4, IL-5, IL-10 and IL-6) ratio was also calculated, which was used to evaluate the host’s overall immune response. The results showed that the Th1/Th2 ratios in patients with ITP and the controls were 3.77±1.34 and 6.67±3.45, respectively, which indicated a relative Th2 polarization in patients with ITP compared with the controls. However, the difference did not reach statistical significance (P>0.05). In addition, a similar trend was observed in the type 1/type 2 ratio between patients with ITP and controls, with ratios of 3.14±1.07 and 4.23±1.48, respectively (P>0.05; Table II, Fig. 3). Furthermore, no significant difference was observed in either the Th1/Th2 ratio or the type 1/type 2 ratio between patients with ITP with platelet counts >20×109/l and patients with platelet counts ≤20×109/l or the controls (Table III, Fig. 4).

Table II

Results of serum cytokine profiling in patients with ITP and controls.

Table II

Results of serum cytokine profiling in patients with ITP and controls.

Cytokine level (pg/ml)

CytokineITPControlP-value
IFN-γ116.38±88.7920.03±7.35>0.05
IL-1016.05±7.034.20±0.95>0.05
IL-12p70131.92±90.7424.59±13.96>0.05
IL-1β39.47±20.9618.94±5.67>0.05
IL-251.12±24.0416.13±6.54>0.05
IL-4306.84±207.5996.27±54.69>0.05
IL-55.52±2.262.19±0.73>0.05
IL-62.66±1.751.36±1.00>0.05
IL-8105.59±77.2436.08±9.92>0.05
TNF-α88.68±65.0118.65±6.73>0.05
TNF-β0.60±0.600.00±0.00>0.05

[i] Results are the mean ± standard deviation. ITP, immune thrombocytopenia; IFN, interferon; IL, interleukin; TNF, tumor necrosis factor.

Table III

Results of serum cytokine profiling in patients with ITP with severe (PLT ≤20×109/l) and moderate (PLT >20×109/l) thrombocytopenia and controls.

Table III

Results of serum cytokine profiling in patients with ITP with severe (PLT ≤20×109/l) and moderate (PLT >20×109/l) thrombocytopenia and controls.

Cytokine level (pg/ml)

CytokineITP (PLT ≤20×109/l)ITP (PLT >20×109/l)ControlP-value
IFN-γ17.64±9.29194.34±158.2520.03±7.35>0.05
IL-1016.67±11.9415.56±8.644.20±0.95>0.05
IL-12p7022.01±12.39218.68±161.1524.59±13.96>0.05
IL-1β27.02±21.6249.29±33.7918.94±5.67>0.05
IL-239.59±19.6660.23±40.5916.13±6.54>0.05
IL-464.34±48.44498.29±367.8796.27±54.69>0.05
IL-56.52±4.434.72±2.142.19±0.73>0.05
IL-60.94±0.664.02±3.091.36±1.00>0.05
IL-845.02±31.92153.42±136.5936.08±9.92>0.05
TNF-α20.32±9.29142.64±115.9618.65±6.73>0.05
TNF-β1.37±1.370.00±0.000.00±0.00>0.05

[i] Results are the mean ± standard deviation. ITP, immune thrombocytopenia; PLT, platelet count; IFN, interferon; IL, interleukin; TNF, tumor necrosis factor.

Negative correlation between circulating NKT cells and platelet count

Although the difference in the frequency of circulating NKT cells between the patients with ITP and the controls was marginal, the level of NKT cells in patients with chronic ITP and severe thrombocytopenia (≤20×109/l) was significantly elevated compared with that in either the controls or the patients with moderate thrombocytopenia (>20×109/l). Thus, a correlation analysis was performed between the level of circulating NKT cells and the platelet count in patients with ITP. A negative correlation between platelet count and NKT cell circulation level was revealed by a linear regression analysis in adult patients with chronic ITP (r=−0.373; P=0.033; Fig. 5). In addition, a positive correlation between the frequency of Tregs and the Th1/Th2 ratio was detected in adults with chronic ITP (r=0.451; P = 0.011). Also, the platelet count was positively correlated with serum levels of IL-12p70 (r=0.354; P=0.044), IFN-γ (r=0.365; P=0.037), IL-4 (r=0.354; P=0.044) and TNF-α (r=0.366; P=0.036) in patients with ITP (data not shown). However, the results did not reveal a correlation between circulating Tregs and peripheral NKT cells in adult chronic ITP.

Discussion

NKT cells and Tregs are important in the maintenance of peripheral tolerance in humans. Abnormalities in the levels or quality of NKT cells and Tregs have been implicated in numerous autoimmune diseases. The loss of peripheral tolerance of a host immune system to platelet auto-antigens leads to premature platelet destruction and a variety of clinical presentations in patients with ITP. Liu et al(10) and Sakakura et al(11) observed that levels of circulating Tregs decreased significantly in patients with ITP. However, Yu et al(12) demonstrated that the inhibitory activity, and not the number, of Tregs in the peripheral blood of patients with ITP contributed to the loss of peripheral tolerance in ITP. By contrast, our results showed that levels of circulating Tregs were not decreased significantly in adult chronic ITP, unlike in the controls. This discrepancy may have been due to the different protocols for the identification of Tregs in different studies. Transcription factor FoxP3 has been indicated to be the most efficacious marker for Treg identification to date (18). However, FoxP3 expression was also detected in CD4+ cells with low or negative CD25 antigen and CD8+ cells (18), thereby leading to an inaccurate measurement of Tregs. Liu et al(19) revealed that a phenotype of CD4+CD25+CD127+/− was able to be used reliably as a marker for functional Tregs in humans. Different markers for the identification of Tregs may, to some extent, explain the discrepancy in the measurements of Tregs between different studies, including the present study.

Johansson et al(15) identified that the proliferative potential of peripheral NKT cells was markedly decreased in patients with ITP compared with the control group. Furthermore, the decreased proliferative potential of NKT cells worsened following corticosteroid therapy, which indicated that NKT cells are involved in ITP pathogenesis. Levels of NKT cells were noted to be elevated in the peripheral blood of a female with ITP; these elevated NKT cells inhibited the in vitro proliferation of autologous CD4+ T cells, which indicated the protective role of NKT cells in ITP (20). This observation was further supported by the results of Ho et al(21), which indicated that activated NKT cells inhibited the in vitro proliferation of CD8+ cells, and that CD8+ NKT cells suppressed T cell activation through the killing mechanism of antigen-presenting cells. In the present study, the levels of circulating NKT cells increased in patients with ITP; however, the difference between the patients with ITP and the controls was not statistically significant. Further analysis revealed that NKT cell levels were markedly elevated in adult patients with ITP with severe thrombocytopenia, which suggested the importance of NKT cells in ITP, particularly with severe thrombocytopenia. In addition, our results showed a negative correlation between platelet count and peripheral NKT cells in ITP. Our results and data from other studies further indicate that NKT cells are important in the pathogenesis of ITP. Cao et al(22) observed that plasma levels of IL-22 were significantly increased in patients with active ITP, and high-dose dexamethasone administration reduced IL-22 production and corrected the imbalance between Th1 and Th22 subsets. The NKT cell is an IL-22-secreting cell in vivo(23). Thus, IL-22 and NKT cells in chronic ITP appear to be correlated.

Azuma et al(24) reported that Tregs inhibited the proliferation, cytokine secretion (including IFN-γ, IL-4, IL-13 and IL-10) and cytotoxicity of CD4+ and CD4CD8 NKT cells through a cell-cell contact mechanism. NKT cells, particularly CD4+ NKT cells, promoted Treg proliferation through IL-2 synthesis and secretion (25). However, in the present study, no correlation between NKT cells and Tregs was identified. Additional studies are required to delineate the correlation between these two regulatory T cell subsets in chronic ITP.

In this study, no significant difference was observed in the serum cytokine profiles and the Th1/Th2 and type 1/type 2 ratios between the patients with ITP and the controls. Our data contradicted the results of other studies on serum cytokine profiles in ITP (6,8). However, linear regression analysis showed that the platelet count correlated positively with the serum levels of IL-12p70, IFN-γ, IL-4 and TNF-α in patients with ITP, which implied the involvement of cytokines in ITP.

At present, a direct comparison between different studies is difficult due to the exclusive nature of the ITP diagnosis (26) and the diversity of the disease phenotype. Zehnder et al(27) proposed that a specific labeling and reliable enumeration for platelet antigen-specific T and B cells was necessary in the future. Accordingly, investigations into ITP may be expanded considerably when platelet antigen-specific T and B cell data are combined with the analysis of NKT cells, Tregs and serum cytokine profiles in adult chronic ITP.

Acknowledgements

This study was supported grants from Jinhua Municipal Bureau of Science and Technology (no. 2007-3-040) and the Department of Science & Technology of Zhejiang Province (no. 2010C13011).

References

1 

Rodeghiero F, Stasi R, Gernsheimer T, et al: Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 113:2386–2393. 2009. View Article : Google Scholar : PubMed/NCBI

2 

Gernsheimer T: Chronic idiopathic thrombocytopenic purpura: mechanisms of pathogenesis. Oncologist. 14:12–21. 2009. View Article : Google Scholar : PubMed/NCBI

3 

Zhou B, Zhao H, Yang RC and Han ZC: Multi-dysfunctional pathophysiology in ITP. Crit Rev Oncol Hematol. 54:107–116. 2005. View Article : Google Scholar : PubMed/NCBI

4 

Semple JW: Immune pathophysiology of autoimmune thrombocytopenic purpura. Blood Rev. 16:9–12. 2002. View Article : Google Scholar : PubMed/NCBI

5 

Coopamah MD, Garvey MB, Freedman J and Semple JW: Cellular immune mechanisms in autoimmune thrombocytopenic purpura: An update. Transfus Med Rev. 17:69–80. 2003. View Article : Google Scholar : PubMed/NCBI

6 

Panitsas FP, Theodoropoulou M, Kouraklis A, et al: Adult chronic idiopathic thrombocytopenic purpura (ITP) is the manifestation of a type-1 polarized immune response. Blood. 103:2645–2647. 2004. View Article : Google Scholar : PubMed/NCBI

7 

Wang T, Zhao H, Ren H, et al: Type 1 and type 2 T-cell profiles in idiopathic thrombocytopenic purpura. Haematologica. 90:914–923. 2005.PubMed/NCBI

8 

Zhang J, Ma D, Zhu X, Qu X, Ji C and Hou M: Elevated profile of Th17, Th1 and Tc1 cells in patients with immune thrombocytopenic purpura. Haematologica. 94:1326–1329. 2009. View Article : Google Scholar : PubMed/NCBI

9 

von Boehmer H: Mechanisms of suppression by suppressor T cells. Nat Immunol. 6:338–344. 2005.PubMed/NCBI

10 

Liu B, Zhao H, Poon MC, et al: Abnormality of CD4+CD25+ regulatory T cells in idiopathic thrombocytopenic purpura. Eur J Haematol. 78:139–143. 2007.

11 

Sakakura M, Wada H, Tawara I, et al: Reduced Cd4+Cd25+ T cells in patients with idiopathic thrombocytopenic purpura. Thromb Res. 120:187–193. 2007.

12 

Yu J, Heck S, Patel V, et al: Defective circulating CD25 regulatory T cells in patients with chronic immune thrombocytopenic purpura. Blood. 112:1325–1328. 2008. View Article : Google Scholar : PubMed/NCBI

13 

Kronenberg M and Gapin L: The unconventional lifestyle of NKT cells. Nat Rev Immunol. 2:557–568. 2002.PubMed/NCBI

14 

Wilson SB and Delovitch TL: Janus-like role of regulatory iNKT cells in autoimmune disease and tumor immunity. Nat Rev Immunol. 3:211–222. 2003. View Article : Google Scholar : PubMed/NCBI

15 

Johansson U, Macey MG, Kenny D, Provan D and Newland AC: Alpha-galactosylceramide-driven expansion of human natural killer T cells is inhibited by prednisolone treatment. Br J Haematol. 125:400–404. 2004. View Article : Google Scholar

16 

La Cava A, Van Kaer L and Fu DS: CD4+CD25+ Tregs and NKT cells: regulators regulating regulators. Trends Immunol. 27:322–327. 2006.

17 

Zhang L, Li H, Zhao H, Ji L and Yang R: Hepatitis C virus-related adult chronic idiopathic thrombocytopenic purpura: experience from a single Chinese center. Eur J Haematol. 70:196–197. 2003. View Article : Google Scholar

18 

Ziegler SF: FOXP3: of mice and men. Annu Rev Immunol. 24:209–226. 2006. View Article : Google Scholar : PubMed/NCBI

19 

Liu W, Putnam AL, Xu-Yu Z, et al: CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med. 203:1701–1711. 2006. View Article : Google Scholar : PubMed/NCBI

20 

Johansson U, Macey MG, Kenny D, Provan AB and Newland AC: The role of natural killer T (NKT) cells in immune thrombocytopenia: is strong in vitro NKT cell activity related to the development of remission? Br J Haematol. 129:564–565. 2005. View Article : Google Scholar : PubMed/NCBI

21 

Ho LP, Urban BC, Jones L, Ogg GS and McMichael AJ: CD4CD8αα subset of CD1d-restricted NKT cells controls T cell expansion. J Immunol. 172:7350–7358. 2004.

22 

Cao J, Chen C, Li L, et al: Effects of high-dose dexamethasone on regulating interleukin-22 production and correcting Th1 and Th22 polarization in immune thrombocytopenia. J Clin Immunol. 32:523–529. 2012. View Article : Google Scholar : PubMed/NCBI

23 

Wolk K, Witte E, Witte K, Warszawska K and Sabat R: Biology of interleukin-22. Semin Immunopathol. 32:17–31. 2010. View Article : Google Scholar

24 

Azuma T, Takahashi T, Kunisato A, Kitamura T and Hirai H: Human CD4+ CD25+ regulatory T cells suppress NKT cell functions. Cancer Res. 63:4516–4520. 2003.PubMed/NCBI

25 

Jiang S, Game DS, Davies D, Lombardi G and Lechler RI: Activated CD1d-restricted natural killer T cells secrete IL-2: innate help for CD4+CD25+ regulatory T cells? Eur J Immunol. 35:1193–1200. 2005. View Article : Google Scholar : PubMed/NCBI

26 

Provan D, Stasi R, Newland AC, et al: International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 115:168–186. 2010. View Article : Google Scholar : PubMed/NCBI

27 

Zehnder JL, Semple JW, Imbach P, Neufeld EJ, Buchanan GR and Cines DB: Future research in ITP: an ICIS consensus. Ann Hematol. 89(Suppl 1): S19–S23. 2010. View Article : Google Scholar

Related Articles

Journal Cover

2014-January
Volume 7 Issue 1

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Xu R, Zheng Z, Ma Y, Hu Y, Zhuang S, Wei B and Lu J: Elevated NKT cell levels in adults with severe chronic immune thrombocytopenia. Exp Ther Med 7: 149-154, 2014
APA
Xu, R., Zheng, Z., Ma, Y., Hu, Y., Zhuang, S., Wei, B., & Lu, J. (2014). Elevated NKT cell levels in adults with severe chronic immune thrombocytopenia. Experimental and Therapeutic Medicine, 7, 149-154. https://doi.org/10.3892/etm.2013.1386
MLA
Xu, R., Zheng, Z., Ma, Y., Hu, Y., Zhuang, S., Wei, B., Lu, J."Elevated NKT cell levels in adults with severe chronic immune thrombocytopenia". Experimental and Therapeutic Medicine 7.1 (2014): 149-154.
Chicago
Xu, R., Zheng, Z., Ma, Y., Hu, Y., Zhuang, S., Wei, B., Lu, J."Elevated NKT cell levels in adults with severe chronic immune thrombocytopenia". Experimental and Therapeutic Medicine 7, no. 1 (2014): 149-154. https://doi.org/10.3892/etm.2013.1386